Manufacturing Day 2026

10:00 AM - 10:25 AM ET

Risk calculation under policy uncertainty

Drugmakers are watching and waiting to see how policy changes in Washington could affect their supply chains. Tariff threats still loom for many smaller companies; imports from China are under pressure. How can companies make long-term manufacturing bets in the face of so much whiplash? Join experts to understand the shifting landscape and what comes next.

Liza Craig

Partner

Goodwin Procter

Prashant Yadav

Senior Fellow & Professor

Council on Foreign Relations

Anna Brown

Moderator

News Reporter

Endpoints News

10:30 AM - 10:55 AM ET

Peptides and the changing gray market

GLP1s were just the beginning. Now, consumers are seeking out all types of peptides through a range of above board, gray, and illicit markets — both from the US and abroad. How are compounding pharmacies reacting to the demand for peptides, and would changing FDA policy affect the legitimate supply?

Mark Mikhael

CEO

Olympia Pharmaceuticals and Wesley Pharmaceuticals

Martha Rumore

Of Counsel Head FDA/Compounding Group

Health Law Alliance

Shelby Livingston

Moderator

Health Tech Correspondent

Endpoints News

11:00 AM - 11:30 AM ET

Complex manufacturing and reshoring challenges: CDMO perspectives and new capabilities

A year into shifting trade policy, drugmakers are still recalibrating their manufacturing playbooks — pulling supply chains closer to home and asking more of the partners who build their drugs. In this panel, leaders from Adare Pharma Solutions, Alcami, Bend Bioscience and Enzene discuss how CDMOs are responding to the reshoring push: solving for regional supply chain shifts, scaling from early-phase batches to blockbuster volumes, hitting tighter specs on increasingly complex small molecules, and adopting next-generation platforms like continuous processing and 3D printing. Join the conversation on how manufacturing partners are retooling to keep pace with tomorrow's pipeline.

Timothy Compton

Chief Strategy Officer

Alcami

Russell Miller

VP, Global Sales & Marketing

Enzene

Armando Pedoto

SVP, Italy Operations

Adare Pharma Solutions

David Smithwick

General Manager & Site Head

Bend Bioscience

Elliott Berger

Moderator

Member, Board of Directors & Strategic Advisor

Orientation Marketing

11:35 AM - 12:05 PM ET

From payload linker to patient: Manufacturing strategies for next-generation bioconjugates

Bioconjugates are transforming targeted therapeutics, but their complexity demands a highly coordinated manufacturing strategy. From payload-linker selection and synthesis, conjugation and purification, to clinical supply, commercial manufacturing, and final drug product, every step must be carefully aligned to ensure safety, speed, quality, and scalability.

Christian Seufert

Head of Advanced Synthesis

Lonza

Jaime Green

Moderator

Science Writer

Freelance Journalist

12:10 PM - 12:40 PM ET

Transforming pharma logistics through health chain orchestration

Driven by sophisticated clinical requirements and heightened regulatory scrutiny, traditional supply chains are giving way to Health Chain Orchestration (HCO), a strategic confluence of experts and resources dedicated to delivering healthcare to patients worldwide. This next-generation model is designed to transform complexity into a streamlined, scalable process, while mitigating extreme geopolitical and environmental challenges. We'll discuss how this model ensures precise, white-glove execution that supports patients and advances the future of healthcare.

Dan Bell

SVP Drug Supply, Distribution & Advanced Therapies

Marken

Jaime Green

Moderator

Science Writer

Freelance Journalist

Country